US3608075A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods of treating the menopausal syndrome
Assignee: Wyeth LLC
•
Filing: 1969-07-28
•
Granted: 1971-09-21
•
Expires: 1989-07-28
Abstract
Abstract A method and composition for treatment of the menopausal syndrome in women utilizing, as the treatment agent, a composition containing sodium 17 Beta -dihydroequilin sulfate as the sole estrogenic agent. Sodium 17 Beta -dihydroequilin sulfate may be administered orally or parenterally in the usual dosage forms and adverse side effects are virtually absent at effective dose levels.
Inventors
- 👤 William L Glen
- 👤 Max Gahwyler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 00:33
CPC Classifications
C; C07; C07J; C07J31/00; C07J31/006
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
49 words
The method of treating the menopausal syndrome and symptoms associated therewith by estrogen therapy which consists of administering to the patient, as the sole estrogenic agent, sodium 17 Beta -dihydroequilin sulfate, said sodium 17 Beta -dihydroequilin sulfate being administered in daily dosages rangiNg from 0.1 mg. to 1.0 mg.
Claim 2
Independent Claim
66 words
The method of treating the menopausal syndrome and symptoms associated therewith by estrogen therapy which consists of orally administering to the patients undergoing said menopausal syndrome a pharmaceutical composition which includes sodium 17 Beta 17 Beta -dihydroequilin sulfate as the sole estrogenic agent thereof, said pharmaceutical composition being orally administered in daily dosages ranging from 0.1 mg. to 1.0 mg. of sodium 17 Beta -dihydroequilin sulfate.
Claim 3
Independent Claim
43 words
The method of treating the menopausal syndrome and symptoms associated therewith by administration of estrogenic agents which consists of administering to human patients undergoing said menopausal syndrome a pharmaceutical composition which contains sodium 17 Beta -dihydroequilin sulfate as the sole estrogenic medicament thereof.
Claim 4
Dependent Claim
15 words
The method of claim 4 wherein said sodium 17 Beta -dihydroequilin sulfate is orally administered.
Claim 5
Dependent Claim
15 words
The method of claim 4 wherein said sodium 17 Beta -dihydroequilin sulfate is parenterally administered.
Claim 6
Dependent Claim
38 words
A pharmaceutical composition for treatment of the menopausal syndrome and associated symptoms which contains, as its sole estrogenic agent, sodium 17 Beta -dihydroequilin sulfate, said sodium 17 Beta -dihydroequilin sulfate being associated with a pharmaceutically acceptable carrier therefor.
Claim 7
Dependent Claim
50 words
A pharmaceutical composition for the treatment of the menopausal syndrome and associated symptoms which contains, as its sole estrogenic agent, sodium 17 Beta -dihydroequilin sulfate, said composition being associated with a pharmaceutically acceptable carrier and being present in said pharmaceutical composition in amounts ranging from 0.1 mg. to 1.0 mg.
Claim 8
Dependent Claim
27 words
The pharmaceutical composition defined in claim 7 wherein said pharmaceutically acceptable carrier is a solid, and said pharmaceutical composition is in the form of tablets or capsules.
Claim 9
Dependent Claim
17 words
The pharmaceutical composition as defined in claim 7 wherein said pharmaceutically acceptable carrier is a vegetable oil.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1974-09-20 | 1975-03-22 | 1975-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1978-09-20 | 1979-03-22 | 1979-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1982-09-20 | 1983-03-22 | 1983-09-21 | $7700.00 | Window Closed / Lapsed |